The FDA decision on APP13007, proposed for post-surgical ocular pain and inflammation, is expected on March 4, 2024.Eyenovia Inc. (EYEN) acquired the U.S. commercial rights to APP13007 for post-surgical ocular pain and inflammation from Taiwan-based Formosa Pharmaceuticals last August. If approved, APP13007 would complement Eyenovia’s Mydcombi, a commercially approved mydriasis product for pupillary dilation.EYEN closed Tuesday's (Feb.27, 2024) trading at $2.16, up 9.09%.